C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States (NCT07520188)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the CASCADE-3002 project is to improve access to cervical cancer screening among women with Human Immunodeficiency Virus (HIV) receiving care at U.S.-based CASCADE clinical sites. This study will assess the cervical cancer screening cascade and identify multilevel factors that impede access to screening among women with HIV attending Infectious Disease clinics in Georgia and Maryland. In parallel, the study will explore and develop implementation strategies for human papillomavirus (HPV) self-collection to increase screening uptake, adherence, and appropriate clinical follow-up in this population at elevated risk for cervical cancer. Cervical cancer remains a preventable malignancy; however, women with HIV are at substantially increased risk and experience higher rates of cervical cancer compared with women without HIV. The World Health Organization has called for the global elimination of cervical cancer as a public health problem, defined as fewer than 4 incident cases per 100,000 women annually, with targets for vaccination, screening, and treatment coverage. Although the United States has the tools to approach near-elimination, disparities in healthcare access and screening persist, particularly among women with HIV.
Who can join: Review the eligibility criteria below.
Location: Emory University SOM Division/Department: Gynecology & Obstetrics — Atlanta, Georgia
Age range: 25 Years to 49 Years
🧪 Interventions in This Study
- Qualitative interviews (BEHAVIORAL)
- Focus groups (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Emory University SOM Division/Department: Gynecology & Obstetrics — Atlanta, Georgia
- University of Maryland School of Medicine Division of Family and Community Medicine — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (919) 966-4432
Email: jennifers@unc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Human Immunodeficiency Virus (HIV)
- The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV — Marietta, Georgia
- Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care — New York, New York
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) — Birmingham, Alabama
- Persuasive Health Communication Intervention for HIV/HCV — New York, New York
- Reducing Systemic Inflammation in People on Antiretroviral Therapy — Montreal, Quebec
Explore by condition: All Human Immunodeficiency Virus (HIV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.